Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial.

Autor: Gavilondo JV; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba. Electronic address: jorge.gavilondo@cigb.edu.cu., Hernández-Bernal F; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Ayala-Ávila M; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., de la Torre AV; 'Celestino Hernández' Hospital, Santa Clara, Villa Clara, Cuba., de la Torre J; Center of Medical and Surgical Research (CIMEQ), Havana, Cuba., Morera-Díaz Y; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Bequet-Romero M; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Sánchez J; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Valenzuela CM; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Martín Y; 'Celestino Hernández' Hospital, Santa Clara, Villa Clara, Cuba., Selman-Housein KH; Center of Medical and Surgical Research (CIMEQ), Havana, Cuba., Garabito A; 'Celestino Hernández' Hospital, Santa Clara, Villa Clara, Cuba., Lazo OC; Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.

Publikováno v: Vaccine [Vaccine] 2014 Apr 17; Vol. 32 (19), pp. 2241-50. Date of Electronic Publication: 2014 Feb 11.